Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A
Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca 2+ -activated CI″ channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A inhibitors have potential utility for treatment or management of disorders of epithelial fluid and mucus secretion, hypertension, some cancers, pain, and other diseases.
1. A compound having one of the following structures (I-5), (I-6) or (I′-6)
or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof,
wherein:
R 1 is optionally substituted C 1 -C 6 alkylene or optionally substituted heteroalkylene;
each R 2 is the same or different and independently hydrogen, methyl, ethyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, or C 1 -C 6 haloalkoxy; and
R 3 is C 1 -C 6 haloalkyl having at least two different halogens.
2. The compound of claim 1 , having one of the following structures (I-7), (I-8) or (I′-8):
wherein:
each R 2 is independently H, methyl, ethyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, or C 1 -C 6 haloalkoxy; and
R 3 is C 1 -C 6 haloalkyl having at least two different halogens.
3. The compound of claim 1 being:
2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide;
2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide;
2-(2,2-Difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide;
2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide;
2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide; or
2-(2,2-difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide.
4. The compound of claim 1 wherein R 2 is H, methyl, ethyl, trifluoromethyl, or trifluoromethoxy.
5. The compound of claim 4 , wherein R 3 is perhaloalkyl.
6. The compound of claim 5 wherein R 3 is chlorodifluoromethyl, bromodifluoromethyl, or difluoroiodomethyl.
7. A pharmaceutical composition comprising a physiologically acceptable excipient and a compound of claim 1 .
8. The pharmaceutical composition of claim 7 wherein the compound of Formula (I) is:
2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide;
2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide;
2-(2,2-Difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide;
2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide;
2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide; or
2-(2,2-difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide.
9. A compound selected from the group consisting of:
2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid (4-fluoro-phenyl)-amide;
2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid (4-fluoro-phenyl)-amide; and
2-(2,2-difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid (4-fluoro-phenyl)-amide.